New insights into HER2-low breast cancer brain metastasis: A retrospective analysis
CONCLUSIONS: Patients diagnosed with HER2-low BCBM exhibited a more favorable prognosis than those with HER2-zero BCBM, particularly within the HR-negative subgroup. The low expression of HER2 is supposed to be linked to the prolonged survival of BCBM patients.PMID:38176304 | DOI:10.1016/j.breast.2023.103669 (Source: Breast)
Source: Breast - January 4, 2024 Category: Cancer & Oncology Authors: Hangcheng Xu Yan Wang Li Li Yiqun Han Yun Wu Qiang Sa Binghe Xu Jiayu Wang Source Type: research
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & amp; epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes
CONCLUSIONS: In conclusion, this study confirms the significance of dds adjuvant chemotherapeutic regimen in terms of long-term survival outcome, safety and toxicity as well as the prognostic significance of TILs and infiltrating CD8+ lymphocytes in BC patients with early-stage disease.PMID:38176305 | DOI:10.1016/j.breast.2023.103668 (Source: Breast)
Source: Breast - January 4, 2024 Category: Cancer & Oncology Authors: Foteinos-Ioannis Dimitrakopoulos Anna Goussia Georgia-Angeliki Koliou Katerina Dadouli Anna Batistatou Helen P Kourea Mattheos Bobos Petroula Arapantoni-Dadioti Olympia Tzaida Triantafyllia Koletsa Sofia Chrisafi Maria Sotiropoulou Alexandra Papoudou-Bai Source Type: research
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data
Breast. 2023 Dec 22;73:103667. doi: 10.1016/j.breast.2023.103667. Online ahead of print.ABSTRACTAntiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line wit...
Source: Breast - December 31, 2023 Category: Cancer & Oncology Authors: Yasmine Rhanine Herv é Bonnefoi Anthony Goncalves Marc Debled Sylvestre Le Moulec Nathalie Bonichon Gaetan Macgrogan Monica Arnedos B énédicte Dubroca-Dehez Thomas Grellety Source Type: research
Corrigendum to 'Assessment of deep learning-based auto-contouring on interobserver consistency in target volume and organs-at-risk delineation for breast cancer: Implications for RTQA program in a multi-institutional study' [The Breast 73 (2024) 103599]
Breast. 2023 Dec 30:103624. doi: 10.1016/j.breast.2023.103624. Online ahead of print.NO ABSTRACTPMID:38161095 | DOI:10.1016/j.breast.2023.103624 (Source: Breast)
Source: Breast - December 31, 2023 Category: Cancer & Oncology Authors: Min Seo Choi Jee Suk Chang Kyubo Kim Jin Hee Kim Tae Hyung Kim Sungmin Kim Hyejung Cha Oyeon Cho Jin Hwa Choi Myungsoo Kim Juree Kim Tae Gyu Kim Seung-Gu Yeo Ah Ram Chang Sung-Ja Ahn Jinhyun Choi Ki Mun Kang Jeanny Kwon Taeryool Koo Mi Young Kim Seo Hee C Source Type: research
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data
Breast. 2023 Dec 22;73:103667. doi: 10.1016/j.breast.2023.103667. Online ahead of print.ABSTRACTAntiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line wit...
Source: Breast - December 31, 2023 Category: Cancer & Oncology Authors: Yasmine Rhanine Herv é Bonnefoi Anthony Goncalves Marc Debled Sylvestre Le Moulec Nathalie Bonichon Gaetan Macgrogan Monica Arnedos B énédicte Dubroca-Dehez Thomas Grellety Source Type: research
Corrigendum to 'Assessment of deep learning-based auto-contouring on interobserver consistency in target volume and organs-at-risk delineation for breast cancer: Implications for RTQA program in a multi-institutional study' [The Breast 73 (2024) 103599]
Breast. 2023 Dec 30:103624. doi: 10.1016/j.breast.2023.103624. Online ahead of print.NO ABSTRACTPMID:38161095 | DOI:10.1016/j.breast.2023.103624 (Source: Breast)
Source: Breast - December 31, 2023 Category: Cancer & Oncology Authors: Min Seo Choi Jee Suk Chang Kyubo Kim Jin Hee Kim Tae Hyung Kim Sungmin Kim Hyejung Cha Oyeon Cho Jin Hwa Choi Myungsoo Kim Juree Kim Tae Gyu Kim Seung-Gu Yeo Ah Ram Chang Sung-Ja Ahn Jinhyun Choi Ki Mun Kang Jeanny Kwon Taeryool Koo Mi Young Kim Seo Hee C Source Type: research
Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
CONCLUSIONS: HR positive and HR negative HER2-low breast cancer exhibit different clinicopathological features, response to NAC and HER2 evolution after treatment.PMID:38159433 | DOI:10.1016/j.breast.2023.103666 (Source: Breast)
Source: Breast - December 30, 2023 Category: Cancer & Oncology Authors: Yingbo Shao Huijuan Guan Zhifen Luo Yang Yu Yaning He Qi Chen Chaojun Liu Fangyuan Zhu Hui Liu Source Type: research
Is there a link between elevated C-reactive protein levels and specific breast cancer molecular subtypes?
Breast. 2023 Dec 9;73:103621. doi: 10.1016/j.breast.2023.103621. Online ahead of print.NO ABSTRACTPMID:38096710 | DOI:10.1016/j.breast.2023.103621 (Source: Breast)
Source: Breast - December 14, 2023 Category: Cancer & Oncology Authors: Kadri Altundag Source Type: research
Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement
Breast. 2023 Dec 10;73:103620. doi: 10.1016/j.breast.2023.103620. Online ahead of print.ABSTRACTBreast cancers (BC) are rare in men and are often caused by constitutional predisposing factors. In women, mosaic BRCA1 promoter methylations (MBPM) are frequent events, detected in 4-8% of healthy subjects. This constitutional epimutation increases risk of early-onset and triple-negative BC. However, the role of MBPM in male BC predisposition has never been assessed. We screened 40 blood samples from men affected by BC, and performed extensive tumour analysis on MBPM-positive patients. We detected two patients carrying MBPM. Su...
Source: Breast - December 14, 2023 Category: Cancer & Oncology Authors: Mathias Schwartz Sabrina Ibadioune Sophie Vacher Marie-Charlotte Villy Olfa Trabelsi-Grati Jessica Le Gall Sandrine M Caputo H élène Delhomelle Mathilde Warcoin Virginie Moncoutier Christine Bourneix Nadia Boutry-Kryza Antoine De Pauw Marc-Henri Stern B Source Type: research
Is there a link between elevated C-reactive protein levels and specific breast cancer molecular subtypes?
Breast. 2023 Dec 9;73:103621. doi: 10.1016/j.breast.2023.103621. Online ahead of print.NO ABSTRACTPMID:38096710 | DOI:10.1016/j.breast.2023.103621 (Source: Breast)
Source: Breast - December 14, 2023 Category: Cancer & Oncology Authors: Kadri Altundag Source Type: research
Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement
Breast. 2023 Dec 10;73:103620. doi: 10.1016/j.breast.2023.103620. Online ahead of print.ABSTRACTBreast cancers (BC) are rare in men and are often caused by constitutional predisposing factors. In women, mosaic BRCA1 promoter methylations (MBPM) are frequent events, detected in 4-8% of healthy subjects. This constitutional epimutation increases risk of early-onset and triple-negative BC. However, the role of MBPM in male BC predisposition has never been assessed. We screened 40 blood samples from men affected by BC, and performed extensive tumour analysis on MBPM-positive patients. We detected two patients carrying MBPM. Su...
Source: Breast - December 14, 2023 Category: Cancer & Oncology Authors: Mathias Schwartz Sabrina Ibadioune Sophie Vacher Marie-Charlotte Villy Olfa Trabelsi-Grati Jessica Le Gall Sandrine M Caputo H élène Delhomelle Mathilde Warcoin Virginie Moncoutier Christine Bourneix Nadia Boutry-Kryza Antoine De Pauw Marc-Henri Stern B Source Type: research
Is there a link between elevated C-reactive protein levels and specific breast cancer molecular subtypes?
Breast. 2023 Dec 9;73:103621. doi: 10.1016/j.breast.2023.103621. Online ahead of print.NO ABSTRACTPMID:38096710 | DOI:10.1016/j.breast.2023.103621 (Source: Breast)
Source: Breast - December 14, 2023 Category: Cancer & Oncology Authors: Kadri Altundag Source Type: research
Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement
Breast. 2023 Dec 10;73:103620. doi: 10.1016/j.breast.2023.103620. Online ahead of print.ABSTRACTBreast cancers (BC) are rare in men and are often caused by constitutional predisposing factors. In women, mosaic BRCA1 promoter methylations (MBPM) are frequent events, detected in 4-8% of healthy subjects. This constitutional epimutation increases risk of early-onset and triple-negative BC. However, the role of MBPM in male BC predisposition has never been assessed. We screened 40 blood samples from men affected by BC, and performed extensive tumour analysis on MBPM-positive patients. We detected two patients carrying MBPM. Su...
Source: Breast - December 14, 2023 Category: Cancer & Oncology Authors: Mathias Schwartz Sabrina Ibadioune Sophie Vacher Marie-Charlotte Villy Olfa Trabelsi-Grati Jessica Le Gall Sandrine M Caputo H élène Delhomelle Mathilde Warcoin Virginie Moncoutier Christine Bourneix Nadia Boutry-Kryza Antoine De Pauw Marc-Henri Stern B Source Type: research
Is there a link between elevated C-reactive protein levels and specific breast cancer molecular subtypes?
Breast. 2023 Dec 9;73:103621. doi: 10.1016/j.breast.2023.103621. Online ahead of print.NO ABSTRACTPMID:38096710 | DOI:10.1016/j.breast.2023.103621 (Source: Breast)
Source: Breast - December 14, 2023 Category: Cancer & Oncology Authors: Kadri Altundag Source Type: research
Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement
Breast. 2023 Dec 10;73:103620. doi: 10.1016/j.breast.2023.103620. Online ahead of print.ABSTRACTBreast cancers (BC) are rare in men and are often caused by constitutional predisposing factors. In women, mosaic BRCA1 promoter methylations (MBPM) are frequent events, detected in 4-8% of healthy subjects. This constitutional epimutation increases risk of early-onset and triple-negative BC. However, the role of MBPM in male BC predisposition has never been assessed. We screened 40 blood samples from men affected by BC, and performed extensive tumour analysis on MBPM-positive patients. We detected two patients carrying MBPM. Su...
Source: Breast - December 14, 2023 Category: Cancer & Oncology Authors: Mathias Schwartz Sabrina Ibadioune Sophie Vacher Marie-Charlotte Villy Olfa Trabelsi-Grati Jessica Le Gall Sandrine M Caputo H élène Delhomelle Mathilde Warcoin Virginie Moncoutier Christine Bourneix Nadia Boutry-Kryza Antoine De Pauw Marc-Henri Stern B Source Type: research
